Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Lipton

Showing results (101-110 of 148) with videos related to

Pageof 15
Sort By:
Plos One|January 10, 2013
Elevation in inflammatory serum biomarkers predicts response to trastuzumab-containing therapyAhmed A Alkhateeb, Kim Leitzel, Suhail M Ali, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 7, 2013
Identification of PTHrP(12-48) as a plasma biomarker associated with breast cancer bone metastasisCharity L Washam, Stephanie D Byrum, Kim Leitzel, et al.
Cancer|October 19, 2006
Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancerChristopher Souder, Kim Leitzel, Suhail M Ali, et al.
Plos One|May 23, 2013
RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitroSandra Casimiro, Khalid S Mohammad, Ricardo Pires, et al.
Cancer Metastasis Reviews|April 30, 2022
Oncobiology and treatment of breast cancer in young womenRakesh Kumar, Catarina Abreu, Masakazu Toi, et al.
Journal of the National Cancer Institute|January 6, 2005
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumorsJanet E Brown, Richard J Cook, Pierre Major, et al.
Leukemia Research|September 29, 2009
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agentsEvangelos Terpos, Meletios A Dimopoulos, Vikas Shrivastava, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2005
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acidRobert E Coleman, Pierre Major, Allan Lipton, et al.
Cancer|July 29, 2008
Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancerSuhail M Ali, Walter P Carney, Francisco J Esteva, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 4, 2017
PTHrP(12-48) Modulates the Bone Marrow Microenvironment and Suppresses Human Osteoclast Differentiation and LifespanArchana Kamalakar, Charity L Washam, Nisreen S Akel, et al.
Pageof 15

Showing results (101-110 of 148) with videos related to

Sort By:
Pageof 15
Plos One|January 10, 2013
Elevation in inflammatory serum biomarkers predicts response to trastuzumab-containing therapyAhmed A Alkhateeb, Kim Leitzel, Suhail M Ali, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 7, 2013
Identification of PTHrP(12-48) as a plasma biomarker associated with breast cancer bone metastasisCharity L Washam, Stephanie D Byrum, Kim Leitzel, et al.
Cancer|October 19, 2006
Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancerChristopher Souder, Kim Leitzel, Suhail M Ali, et al.
Plos One|May 23, 2013
RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitroSandra Casimiro, Khalid S Mohammad, Ricardo Pires, et al.
Cancer Metastasis Reviews|April 30, 2022
Oncobiology and treatment of breast cancer in young womenRakesh Kumar, Catarina Abreu, Masakazu Toi, et al.
Journal of the National Cancer Institute|January 6, 2005
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumorsJanet E Brown, Richard J Cook, Pierre Major, et al.
Leukemia Research|September 29, 2009
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agentsEvangelos Terpos, Meletios A Dimopoulos, Vikas Shrivastava, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2005
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acidRobert E Coleman, Pierre Major, Allan Lipton, et al.
Cancer|July 29, 2008
Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancerSuhail M Ali, Walter P Carney, Francisco J Esteva, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 4, 2017
PTHrP(12-48) Modulates the Bone Marrow Microenvironment and Suppresses Human Osteoclast Differentiation and LifespanArchana Kamalakar, Charity L Washam, Nisreen S Akel, et al.
Pageof 15